BRPI0920622A2 - vacina contra vírus da doença equina africana - Google Patents

vacina contra vírus da doença equina africana

Info

Publication number
BRPI0920622A2
BRPI0920622A2 BRPI0920622A BRPI0920622A BRPI0920622A2 BR PI0920622 A2 BRPI0920622 A2 BR PI0920622A2 BR PI0920622 A BRPI0920622 A BR PI0920622A BR PI0920622 A BRPI0920622 A BR PI0920622A BR PI0920622 A2 BRPI0920622 A2 BR PI0920622A2
Authority
BR
Brazil
Prior art keywords
disease virus
virus vaccine
equine disease
african equine
african
Prior art date
Application number
BRPI0920622A
Other languages
English (en)
Inventor
Alan John Guthrie
Jean-Christophe Audonnet
Jiansheng Yao
Jules Maarten
Nigel James Maclachlan
Original Assignee
Merial Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41818403&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0920622(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merial Ltd filed Critical Merial Ltd
Priority to BR122019001455-8A priority Critical patent/BR122019001455B1/pt
Publication of BRPI0920622A2 publication Critical patent/BRPI0920622A2/pt
Publication of BRPI0920622A8 publication Critical patent/BRPI0920622A8/pt
Publication of BRPI0920622B1 publication Critical patent/BRPI0920622B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12111—Orbivirus, e.g. bluetongue virus
    • C12N2720/12134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0920622-1A 2008-10-24 2009-10-22 vacina contra o vírus da doença equina africana BRPI0920622B1 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122019001455-8A BR122019001455B1 (pt) 2008-10-24 2009-10-22 vacina contra o vírus da doença equina africana

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10807508P 2008-10-24 2008-10-24
US16351709P 2009-03-26 2009-03-26
PCT/US2009/061669 WO2010048394A2 (en) 2008-10-24 2009-10-22 Vaccine against african horse sickness virus

Publications (3)

Publication Number Publication Date
BRPI0920622A2 true BRPI0920622A2 (pt) 2016-10-04
BRPI0920622A8 BRPI0920622A8 (pt) 2019-02-05
BRPI0920622B1 BRPI0920622B1 (pt) 2019-11-12

Family

ID=41818403

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122019001455-8A BR122019001455B1 (pt) 2008-10-24 2009-10-22 vacina contra o vírus da doença equina africana
BRPI0920622-1A BRPI0920622B1 (pt) 2008-10-24 2009-10-22 vacina contra o vírus da doença equina africana

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122019001455-8A BR122019001455B1 (pt) 2008-10-24 2009-10-22 vacina contra o vírus da doença equina africana

Country Status (19)

Country Link
US (3) US8168200B2 (pt)
EP (1) EP2358742B1 (pt)
JP (1) JP2012506699A (pt)
KR (1) KR101719005B1 (pt)
CN (1) CN102245627A (pt)
AP (1) AP3334A (pt)
AR (1) AR074055A1 (pt)
AU (1) AU2009308331C1 (pt)
BR (2) BR122019001455B1 (pt)
CA (1) CA2741333C (pt)
CL (1) CL2011000922A1 (pt)
EA (1) EA024111B1 (pt)
ES (1) ES2681693T3 (pt)
MX (1) MX2011004219A (pt)
NZ (2) NZ598605A (pt)
PL (1) PL2358742T3 (pt)
PT (1) PT2358742T (pt)
WO (1) WO2010048394A2 (pt)
ZA (1) ZA201103031B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP3334A (en) * 2008-10-24 2015-07-31 Univ California Vaccine against african horse sickness virus
AU2013221502C1 (en) 2012-02-14 2018-03-01 Boehringer Ingelheim Animal Health USA Inc. Recombinant poxviral vectors expressing both rabies and OX40 proteins, and vaccines made therefrom
WO2016071850A1 (en) * 2014-11-04 2016-05-12 Deltamune (Pty) Limited Live attenuated african horsesickness virus
US10334248B2 (en) * 2015-05-29 2019-06-25 Qualcomm Incorporated Coding data using an enhanced context-adaptive binary arithmetic coding (CABAC) design
JP7245260B2 (ja) * 2018-03-19 2023-03-23 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー Ehv挿入部位ul43
US12581092B2 (en) 2022-03-03 2026-03-17 Qualcomm Incorporated Temporal initialization points for context-based arithmetic coding
CN116041447A (zh) * 2022-12-29 2023-05-02 北京亿森宝生物科技有限公司 一种检测非洲马瘟病毒的试剂盒及其应用
CN116656731B (zh) * 2023-05-25 2024-04-12 军事科学院军事医学研究院军事兽医研究所 一种表达非洲猪瘟病毒多种蛋白的重组金丝雀痘病毒及其构建方法
WO2025013146A1 (ja) 2023-07-07 2025-01-16 中京油脂株式会社 分散体
CN117737310B (zh) * 2024-01-26 2024-07-16 中国农业科学院北京畜牧兽医研究所 非洲马瘟和西尼罗病毒的双重实时荧光mira检测引物探针组、试剂盒及方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
WO1992015672A1 (en) * 1991-03-07 1992-09-17 Virogenetics Corporation Genetically engineered vaccine strain
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
ZA976424B (en) * 1996-07-05 1999-01-22 Agricultural Research Council Nucleic acid sequences coding for african horsesickness virus outer capsid components
FR2775601B1 (fr) * 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) * 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
US7740863B2 (en) * 2001-04-06 2010-06-22 Merial Recombinant vaccine against West Nile Virus
US7862821B2 (en) * 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
AP3334A (en) * 2008-10-24 2015-07-31 Univ California Vaccine against african horse sickness virus

Also Published As

Publication number Publication date
US20100119546A1 (en) 2010-05-13
US8168200B2 (en) 2012-05-01
WO2010048394A2 (en) 2010-04-29
AU2009308331C1 (en) 2015-07-09
BRPI0920622A8 (pt) 2019-02-05
EP2358742B1 (en) 2018-02-28
NZ592388A (en) 2012-03-30
CN102245627A (zh) 2011-11-16
MX2011004219A (es) 2011-09-22
US20120114691A1 (en) 2012-05-10
AR074055A1 (es) 2010-12-22
AP3334A (en) 2015-07-31
BR122019001455B1 (pt) 2021-01-19
EA201100674A1 (ru) 2011-12-30
CA2741333A1 (en) 2010-04-29
PT2358742T (pt) 2018-06-04
CA2741333C (en) 2018-02-13
ES2681693T3 (es) 2018-09-14
KR20110092281A (ko) 2011-08-17
EA024111B1 (ru) 2016-08-31
PL2358742T3 (pl) 2018-08-31
AU2009308331B2 (en) 2014-08-21
JP2012506699A (ja) 2012-03-22
CL2011000922A1 (es) 2011-09-16
NZ598605A (en) 2014-04-30
EP2358742A2 (en) 2011-08-24
WO2010048394A3 (en) 2010-08-19
BRPI0920622B1 (pt) 2019-11-12
AU2009308331A1 (en) 2010-04-29
US20140120133A1 (en) 2014-05-01
AP2011005954A0 (en) 2011-10-31
KR101719005B1 (ko) 2017-03-22
ZA201103031B (en) 2014-03-26

Similar Documents

Publication Publication Date Title
IL269427B (en) Vaccine nanotechnology
DK2114993T3 (da) Vaccine
BRPI0917567A2 (pt) tratamento de doença respiratória
DK2481420T3 (da) Enkeltdosis-anti-PCV2-svinevaccine
DK2200646T3 (da) RNA-Vacciner
ATE450271T1 (de) Impfstoff
DK2049559T3 (da) Forbedrede HPV vacciner
BRPI0917205A2 (pt) vacina polivalente
DK1926496T3 (da) PCV-2-vaccine
DK2998315T4 (da) Newcastle sygdomsvirus-bårne fuglevacciner
EP2293813A4 (en) NANO EMULSION VACCINES
EP2293814A4 (en) NANOEMULSION AGENTS
BRPI1006821A2 (pt) composições para o tratamento da doença de refluxo gastro-esofágico (gerd).
BRPI0821034A2 (pt) Vírus influenza modificado
BRPI1011224A2 (pt) vacina contra vírus da dengue inativado com adjuvante livre de alumínio
BRPI0918056A2 (pt) Diaminopirimidinas substituídas por 4-alquila
EP2283031A4 (en) VACCINE AGAINST LYME DISEASE
ZA201103031B (en) Vaccine against african horse sickness virus
SMT201400170B (it) Vaccino contro hpv
ZA200809056B (en) Influenza virus vaccine
DK2422810T3 (da) Influenzavaccine
BRPI1008708A2 (pt) gastroscópio.
EP2442827A4 (en) NANO EMULSION VACCINES
EP2061502A4 (en) CARBOHYDRATE-BASED VACCINES FOR HLV
NO20100811A (no) Subenhetsvaksine for akvakutur

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MERIAL, INC. (US)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 12/11/2019, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) ; UNIVERSITY OF PRETORIA (ZA) ; BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC. (US)